Ascendis Pharma A/S ADR | Mutual Funds
Mutual Funds that own Ascendis Pharma A/S ADR
Catalyst Eventide Gilead Fund
997,000
2.4%
0
3.8%
06/29/2018
T Rowe Price Health Sciences Fund
796,431
1.92%
94,446
0.44%
06/30/2018
Fidelity Select Health Care Portfolio
627,500
1.51%
7,500
0.59%
07/31/2018
Fidelity Small Cap Growth Fund
439,855
1.06%
-2,906
0.68%
04/30/2018
iShares Nasdaq Biotechnology ETF
435,464
1.05%
-5,691
0.32%
09/06/2018
Oppenheimer International Small Company Fund
424,570
1.02%
129,760
0.28%
02/28/2018
HBM BioVentures Ltd.
400,000
0.96%
100,000
1.93%
12/31/2017
T Rowe Price Small Cap Stock Fund
397,087
0.96%
-2,400
0.27%
06/30/2018
Eventide Healthcare & Life Sciences Fund
390,000
0.94%
54,460
3.99%
06/29/2018
Fidelity Blue Chip Growth Fund
389,207
0.94%
0
0.1%
07/31/2018
| Address |
Tuborg Boulevard 12
Hellerup CR 2900
Denmark
|
|
Employees
|
- |
| Website |
http://www.ascendispharma.com |
| Updated |
07/08/2019 |
| Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark. |
